Search academic texts

Information × Registration Number 0224U032311, 0123U103711 , R & D reports Title Use of nanocarriers for enhancement of therapeutic activity of novel anticancer drugs popup.stage_title Використання нанорозмірних носіїв для посилення терапевтичної активності новітніх протипухлинних засобів Head Panchuk Rostyslav R., Доктор біологічних наук Registration Date 09-09-2024 Organization Panchuk Rostyslav Ruslanovych popup.description2 The study demonstrated that the combination of the anticancer drug doxorubicin and the bioactive lipid NSE on a nanoscale poly(VEP-co-GMA)-graft-MEG carrier not only reduces the side effects of doxorubicin by 4 times, but also doubles its therapeutic effect in vivo in mouse models of lymphoma and leukemia. This unique combination of a cytoprotector and an anticancer drug on a single drug delivery platform allows to simultaneously solve two fundamental problems of cancer chemotherapy - 1) to reduce the effective dose of drugs and 2) to protect normal cells from their side effects due to the cytoprotector NSE. It was found that the poly-2-oxazoline carrier inhibits the potentially toxic activity of the experimental anticancer drug landomycin A (LA) against normal cells - its ability to form adducts with cellular thiols, but has virtually no effect on its redox activity, which leads to early generation of hydrogen peroxide in malignant cells within 1 hour after exposure to the drug and their rapid death. Experiments on B16F10 melanoma in mice showed impressive efficacy of the new dosage form of LA, which led to complete tumor remission in 100% of cases, while under the influence of LA in free form, this effect was manifested in only 12.5% of animals, and partial inhibition of tumor growth - in 37.5% of mice. The administration of the nanosized form of LA also revealed a 100% normalization of the ratio of neutrophils and lymphocytes to the levels observed in intact mice. Thus, the work demonstrated the high therapeutic efficacy of the use of novel polymeric nanocarriers to increase the selectivity of both traditional and experimental anticancer drugs. The data obtained indicate significant prospects for the further use of the obtained nanocomposites in clinical practice for the treatment of malignant tumors of various genesis, including those resistant to chemotherapy. Product Description popup.authors popup.nrat_date 2024-10-01 Close